|Bid||11.50 x 1000|
|Ask||11.75 x 4000|
|Day's Range||11.59 - 12.16|
|52 Week Range||6.26 - 19.25|
|Beta (3Y Monthly)||2.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.50|
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
On Friday last week, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced promising updated results from the Phase 1/2 ALTA trial.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Soliton, Inc. (NASDAQ: SOLY ) shares were ...
BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.
Sangamo Therapeutics reported positive data on its gene therapy for hemophilia, and CannTrust Holdings received a noncompliance report from Canadian authorities.
Sangamo stock popped Monday after the biotech company unveiled promising results for its Pfizer-partnered gene therapy in hemophilia A treatment. Sangamo stock jumped as much as 16.9%.
Sangamo Therapeutics (NASDAQ:SGMO) stock was on the up and up to kick off the week as the business revealed that it has made some key forward progress in its gene therapy that is designed to treat hemophilia A.Source: Shutterstock The Richmond, Calif.-based business revealed on Friday -- along with its partner Pfizer (NYSE:PFE) -- updated data from its Phase I/II Alta study of SB-525, designed to treat the aforementioned blood ailment. The data was presented in Melbourne, Australia, which hosts the International Society on Thrombosis and Haemostasis congress.Sangamo and Pfizer highlighted data that showed, out of the four patients who were given the highest dose of 30 trillion vectors per kilogram, two of them rapidly experienced positive results. They attained normal and sustained levels of Factor VIII with no reported bleeding events or need to receive treatment with the factor for as long as 24 weeks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe other two experienced Factor VIII activity kinetics that was consistent with the first two patients. Sangamo had presented interim data on eight patients that the biotechnology company treated with SB-525 in April, which indicated that the therapy was well-tolerated-the data also showed a dose-dependent increase in Factor VIII levels across the dosage cohorts.The California business was founded in 1995 and it focuses its treatments on helping patients with hemophilia and other genetic illnesses.SGMO stock is up about 3.5% on Monday following the news. More From InvestorPlace * 7 A-Rated Stocks to Buy for the Rest of 2019 * The 7 Top Small-Cap Stocks Of 2019 * 7 F-Rated Stocks to Sell for Summer * 7 Retail Stocks to Buy That Are Down in 2019 The post Sangamo Therapeutics News: SGMO Stock Surges on Gene Therapy Study appeared first on InvestorPlace.
Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.
BRISBANE, Calif. & NEW YORK-- -- The first two patients treated at the 3e13 vg/kg dose level rapidly achieved normal, sustained Factor VIII levels with no reported bleeding events and no factor usage for as long as 24 weeks of follow-up The two patients more recently treated at the 3e13 vg/kg dose level demonstrated FVIII activity kinetics that appear consistent with the first two patients in this ...
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
By John Vandermosten, CFA American Gene Technologies (AGT) is a genetic medicines company developing a portfolio of therapies that employ the company’s proprietary lentiviral vector (LV) platform to focus ...
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-factors (ZFP-TFs) in preclinical models of Huntington’s disease (HD). The publication describes research by Sangamo and collaborators at the CHDI Foundation, in which ZFP-TFs were engineered to selectively target the mutant form of the huntingtin gene (HTT) and repress its transcription, selectively lowering production of the mutant Huntingtin protein (mHTT). Preclinical data from HD patient-derived fibroblasts and neurons demonstrated that a single administration of ZFP-TFs resulted in the selective repression of over 99% of HD-causing HTT disease alleles over a wide dose range, while preserving the expression of at least 86% of healthy wild-type HTT alleles.
Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. Here ...
BRISBANE, Calif. , June 21, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced the upcoming presentation of data from the Phase 1/2 Alta study evaluating ...
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
BioMarin's gene therapy for hemophilia A dropped potentially life-threatening bleeding events from more than a dozen to zero.
Hemophilia A SB-525 gene therapy clinical data accepted for oral presentation at ISTH BRISBANE, Calif. , May 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, ...
BRISBANE, Calif., May 10, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Sangamo will participate in the Bank of America Merrill Lynch 2019 Health Care Conference being ...